Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
2026-03-13 09:18:29 ET
Sphera Funds Management disclosed a buy of 279,974 shares of Cogent Biosciences (NASDAQ:COGT) in a February 17, 2026, SEC filing, an estimated $7.87 million transaction based on quarterly average pricing.
According to its SEC filing dated February 17, 2026, Sphera Funds Management Ltd. increased its holdings in Cogent Biosciences by 279,974 shares. The estimated value of this transaction, based on the average closing price during the fourth quarter of 2025, is approximately $7.87 million. The position’s value at quarter-end rose by $12.03 million, a figure that includes both the additional shares and changes in market price.
Cogent Biosciences is a clinical-stage biotechnology company specializing in precision therapies for genetically driven diseases. The company's strategic focus on targeted inhibitors for rare mutations positions it to address significant unmet medical needs in oncology and hematology. With a robust pipeline and partnerships, Cogent aims to leverage scientific innovation to achieve competitive differentiation in the biotechnology sector.
NASDAQ: COGT
COGT Trading
-1.56% G/L:
$35.34 Last:
614,078 Volume:
$35.68 Open:
